Metagenomi Therapeutics (MGX) Change in Acquisitions & Divestments (2023 - 2025)

Metagenomi (MGX) has disclosed Change in Acquisitions & Divestments for 3 consecutive years, with $52.0 million as the latest value for Q4 2025.

  • Quarterly Change in Acquisitions & Divestments rose 26.15% to $52.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $170.5 million through Dec 2025, down 22.99% year-over-year, with the annual reading at $170.5 million for FY2025, 22.99% down from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was $52.0 million at Metagenomi, up from $33.5 million in the prior quarter.
  • The five-year high for Change in Acquisitions & Divestments was $101.5 million in Q4 2023, with the low at $33.5 million in Q3 2025.
  • Average Change in Acquisitions & Divestments over 3 years is $54.6 million, with a median of $48.6 million recorded in 2023.
  • Peak annual rise in Change in Acquisitions & Divestments hit 81.62% in 2024, while the deepest fall reached 59.38% in 2024.
  • Over 3 years, Change in Acquisitions & Divestments stood at $101.5 million in 2023, then tumbled by 59.38% to $41.2 million in 2024, then grew by 26.15% to $52.0 million in 2025.
  • According to Business Quant data, Change in Acquisitions & Divestments over the past three periods came in at $52.0 million, $33.5 million, and $37.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.